FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 20th, 2023 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (“First Amendment”) is made as of April 17, 2023 by and between Immune Ventures, LLC (“Licensor”) and INmune Bio, Inc., a Nevada corporation, having a principal place of business at 225 NE Mizner Blvd., STE 640, Boca Raton, FL 33432 (“Licensee”), each a “Party” and collectively the “Parties”.
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 20th, 2023 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Second Amendment”) is made as of April 6, 2023, by and between the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania (“University”) and INmune Bio, Inc (“Licensee”).
